Preview

Rational Pharmacotherapy in Cardiology

Advanced search

From Low-Dose Fixed Combinations for Arterial Hypertension Treatment to Multi-Target Therapy of Cardiovascular Diseases

https://doi.org/10.20996/1819-6446-2020-08-03

Full Text:

Abstract

The article presents the evolutionary development of combination therapy from the creation of a multicomponent tablet for the treatment of arterial hypertension (AH) to modern multi-target fixed combinations as the most effective approach to the fight against cardiovascular diseases (CVD). The priority of domestic scientists, in particular academician A.L. Myasnikov, in the development and creation of a combined drug for AH treatment is shown. The development of pharmacology and pharmaceutical technologies has allowed to expand the range of possible drug combinations for AH therapy, and the discovery of new pathophysiological mechanisms involved in the cardiovascular continuum has led to the understanding of the close links between AH and atherosclerosis. This fact prompted the scientific community to search for and implement in practice drug combinations that would allow multi-target therapy, that is, to influence several pathological processes and achieve a number of therapeutic goals. The presented review testifies to the transformation of the concept of fixed combinations for patients with AH into the concept of a multi-target drug. Multi-targeting is achieved not only by the pleotropic of components known as hypotensive agents, but also by combination with statins. Taking into account the wide AH prevalence in the population, its high medical and social significance, the critical importance as a risk factor for CVD, the authors consider a justified clinical and epidemiological approach to primary prevention of CVD with the widespread use of multi-targeted therapy in all high-risk patients with AH. It is expedient to develop new domestic medicines that implement the concept of a multi-targeted drug, to include them in the list of vital medicines, to increase the availability of these drugs to the population on the basis of preferential programs.

About the Authors

P. A. Lebedev
Samara State Medical University
Russian Federation

Petr A. Lebedev – MD, PhD, Professor, Chair of Therapy

Artsybushevskaya ul. 171, Samara, 443001



A. A. Garanin
Samara State Medical University
Russian Federation

Andrei A. Garanin – MD, PhD, Assistant, Chair of Propedeutic Therapy

Artsybushevskaya ul. 171, Samara, 443001



References

1. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-23. DOI:10.1136/bmj.326.7404.1419.

2. Golikov A.P. Crises in hypertension yesterday and today. Arterial'naja Gipertenzija. 2004;10(3):147- 51 (In Russ.) DOI:10.18705/1607-419X-2004-10-3-147-151.

3. Baryshnikova G.A., Chorbinskaja S.A., Stepanova I.I., Ljalina S.V. Poliphilus as a means to increase the effectiveness of treatment patients with high cardiovascular risk. Trudnyj pacient. 2015;7:6-11 (In Russ.) DOI:10.26442/2075-1753_19.10.13-18.

4. Svirjaev Ju.V. Combination therapy of hypertension-is it time to "polypill"? Arterial'naja Gipertenzija. 2009;15(4):458-61 (In Russ.) DOI:10.18705/1607-419X-2009-15-4-458-461.

5. Konradi A.O. Conservative drug therapy of patients with resistant arterial hypertension is a time of compromise. Medicinskij Sovet. 2013;(9):17-25 (In Russ.) DOI:10.21518/2079-701X-2013-9-17-25

6. Mjasnikov A.L. Fundamentals of diagnosis and particular pathology (propaedeutics) of internal diseases. Moscow: Medgiz; 1952 (In Russ.)

7. Mjasnikov A.L. Hypertension and atherosclerosis. Moscow: Medicina; 1965 (In Russ.)

8. Chekman I.S., Peleschuk A.P., Pyatak O.A., ed. Clinical Pharmacology and Pharmacotherapy Handbook. Kiev: Zdorov'e; 1987 (In Russ.)

9. Nesterov V.S. Clinical manifestations of diseases of the heart and blood vessels. Kiev: Zdorov'e; 1971 (In Russ.)

10. Abdullaev R.A. Clinical lectures on topical issues of cardiology. Tashkent: Medicina; 1980 (In Russ.)

11. Ganelina I.E., ed. Coronary heart disease. Leningrad: Medicine; 1977 (In Russ.)

12. Shelagurov A. A. Propedeutics of Internal Medicine. Moscow: Medicina; 1975 (In Russ.)

13. Kassirsky I.A., ed. Therapist's handbook. Moscow: Medicine; 1969 (In Russ.)

14. Cressman M.D., Gifford R.W. Controversies in hypertension: mild hypertension, isolated systolic and the choice of a step one drug. Clin Cardiol. 1983;6(1):1-10.

15. Saklayen M.G., Deshpande N.V. Timeline of history of hypertension treatment. Front Cardiovasc Med. 2016;3:3. DOI:10.3389/fcvm.2016.00003.

16. Konradi A.O. New in non-drug and drug treatment of hypertension in 2013 (review of recommendations for diagnosis and treatment of hypertension ESH/ESC 2013). Arterial'naja Gipertenzija. 2014;20(1):34-7 (In Russ.) DOI:10.18705/1607-419X-2014-20-1-34-37.

17. Iskakov E.B. Epidemiology of cardiovascular diseases. Medicina i Jekologija. 2017;2:19-28 (In Russ.)

18. Chazova I.E., Ratova L.G. Hypertension: from A.L. Myasnikov to the present day. Kardiologicheskij Vestnik. 2010;5(1):5-10 (In Russ.)

19. Yusuf S., Lonn E., Pais P., et al. Blood pressure and cholesterol in persons without cardiovascular diseases. N Engl J Med. 2016;374:2032-43. DOI:101056/NEJMoa1600177.

20. Chazova I.E., Zhernakova Ju.V. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Sistemnye Gipertenzii. 2019;16(1):6-31 (In Russ.) DOI:10.26442/2075082X.2019.1.190179.

21. Wang Y.C., Hsieh T.C., Chou C.L., Wu J.L., Fang T.C. Risks of adverse events following coprescription of statins and calcium channel blockers. Medicine (Baltimore). 2016;95(2):e2487. DOI:10.1097/MD.0000000000002487.

22. Konyi A., Sarszegi Z., Hild G., Gaszner B. Safety and effectiveness of cjmbined antihypertensive and cholesterol lowering therapy in high/very high risk patients. J Comp Eff Res. 2016;13;5(4):355-64. DOI:10.2217/cer-2016-0003.

23. Karpov Y.A., Lyalina S.V. The TRIUMVIRATE Study: reducing the risk of cardiovascular events in hypertensive patients using triple combination antihypertensive and lipid-lowering drugs. Kardiologiia. 2015;55(9):10-5 (In Russ.) DOI:10.18565/cardio.2015.9.10-15.

24. Piepoli M.F., Hoes A.W., Agewall S., et al.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. DOI:10.1093/eurheartj/ehw106.


For citation:


Lebedev P.A., Garanin A.A. From Low-Dose Fixed Combinations for Arterial Hypertension Treatment to Multi-Target Therapy of Cardiovascular Diseases. Rational Pharmacotherapy in Cardiology. 2020;16(4):638-643. (In Russ.) https://doi.org/10.20996/1819-6446-2020-08-03

Views: 52


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)